18 beta-glycyrrhetinic acid (18 beta-GA) is a bioactive component of licorice. The anti-cancer activity of 18 beta-GA has been studied in many cancer types, whereas its effects in lung cancer remain largely unknown. We first showed that 18 beta-GA effectively suppressed cell proliferation and inhibited expression as well as activity of thromboxane synthase (TxAS) in non-small cell lung cancer (NSCLC) cells A549 and NCI-H460. In addition, the administration of 18 beta-GA did not have any additional inhibitory effect on the decrease of cell proliferation induced by transfection with TxAS small interference RNA (siRNA). Moreover, 18 beta-GA failed to inhibit cell proliferation in the immortalized human bronchial epithelial cells 16HBE-T and another NSCLC cell line NCI-H23, both of which expressed minimal level of TxAS as compared to A549 and NCI-H460. However, 18 beta-GA abolished the enhancement of cell proliferation induced by transfection of NCI-H23 with pCMV6-TxAS plasmid. Further study found that the activation of both extracellular signal-regulated kinase (ERK)1/2 and cyclic adenosine monophosphate response element binding protein (CREB) induced by TxAS cDNA transfection could be totally blocked by 18 beta-GA. Altogether, we have delineated that, through inhibiting TxAS and its initiated ERK/CREB signaling, 18 beta-GA suppresses NSCLC cell proliferation. Our study has highlighted the significance of 18 beta-GA with respect to prevention and treatment of NSCLC.